Andera Partners is a private equity firm focused on early- and late-stage venture investments.
Business Model:
Revenue: $0
Employees: 0-0
Address: 374 rue Saint Honoré
City: Paris
State: île-de-france
Zip: 75001
Country: FR
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas: Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2021 | Sirsa | Venture Round | - |
1/2023 | Amolyt Pharma | Series C | 0 |
6/2009 | Implanet | Series B | 12.6M |
9/2017 | La Vie Saine | Private Equity Round | - |
7/2016 | Fortesan | Venture Round | 16.7M |
9/2021 | Amolyt Pharma | Series B | 0 |
4/2016 | MedDay | Series B | 0 |
4/2018 | Crescendo Biologics | Series B | 0 |
8/2018 | Artios Pharma | Series B | 0 |
10/2006 | Domain Therapeutics | Series C | 10.4M |
6/2017 | Minafin | Private Equity Round | - |
12/2009 | Regado Biosciences | Series D | 0 |
10/2008 | SuperSonic Imagine | Series B | 25.7M |
2/2006 | MeeVee | Series B | 6.5M |
4/2013 | Allecra Therapeutics | Series A | 19.6M |
2/2020 | JenaValve Technology | Series D | 0 |
4/2010 | Genticel | Series C | 17.7M |
8/2014 | Groupe ADF | Private Equity Round | - |
11/2011 | In2Bones France | Seed Round | 1.4M |
12/2018 | INNOVO by Atlantic Therapeutics | Private Equity Round | - |
9/2015 | Groupe ERGET | Venture Round | - |
3/2022 | Kyotherm | Venture Round | 0 |
1/2007 | Novexel | Series B | 65M |
6/2022 | ImCheck Therapeutics | Series C | 0 |
9/2009 | Santen Pharmaceutical | Post-IPO Equity | 22M |
12/2012 | Poxel | Series B | 17.2M |
5/2014 | Chase Pharmaceuticals | Series B | 21M |
7/2018 | Dynacure | Series A | 55.2M |
4/2020 | Dynacure | Series C | 54.2M |
9/2010 | Garden Price | Venture Round | 2.7M |
2/2006 | Cytomics Pharmaceuticals | Series B | 11.9M |
3/2005 | Nautilus Biotech | Venture Round | 0 |
8/2015 | JenaValve Technology | Series C | 26.5M |
6/2015 | Realeve | Series D | 43.2M |
7/2013 | JenaValve Technology | Series C | 62.5M |
6/2010 | JenaValve Technology | Series B | 22.7M |
1/2013 | Unitedcoatings Group | Venture Round | 0 |
3/2017 | Medlumics | Series B | 36.9M |
2/2022 | Lhyfe | Venture Round | 0 |
1/2011 | OCEAN SAS | Venture Round | - |
6/2016 | Allecra Therapeutics | Series B | 24.8M |
2/2021 | Medlumics | Venture Round | 21.8M |
7/2021 | Klubb | Venture Round | - |
2/2022 | TargED Biopharmaceuticals | Series A | 0 |
4/2023 | BioVentrix | Series A | 0 |
1/2023 | SoniVie | Series C | 0 |
10/2022 | Senstronic | Venture Round | - |
1/2023 | Grey Wolf Therapeutics | Series B | 0 |
6/2019 | SANIFIT | Series D | 0 |
11/2013 | Endosense | Series C | 41.2M |
2/2016 | Sogetrel | Private Equity Round | - |
12/2001 | Genome Express | Series B | 0 |
9/2019 | Inotrem | Series B | 43.1M |
7/2021 | Artios Pharma | Series C | 0 |
10/2015 | REALEASE Capital | Private Equity Round | - |
10/2012 | ProwebCE | Venture Round | - |
6/2005 | Cellectis | Series C | 6.8M |
6/2007 | Exclusive Group | Venture Round | 4M |
3/2021 | INNOVO by Atlantic Therapeutics | Venture Round | - |
5/2002 | Cellectis | Series B | 7.2M |
4/2023 | Ariceum Therapeutics | Series A | 0 |
10/2021 | Exciva | Series A | 0 |
1/2019 | HighLife | Series B | 36M |
12/2014 | Emeraude International | Private Equity Round | - |
5/2017 | Axonics Modulation Technologies | Series C | 0 |
4/2006 | Santen Pharmaceutical | Post-IPO Equity | 31.5M |
7/2019 | AM Pharma | Series F | 130.1M |
1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
10/2017 | Globe Groupe | Private Equity Round | - |
9/2015 | SANIFIT | Series C | 0 |
11/2010 | SuperSonic Imagine | Series C | 0 |
10/1999 | Drug Abuse Sciences | Venture Round | 22.4M |
10/2014 | Thomson Video Networks | Private Equity Round | - |
9/2016 | MS Vacances | Venture Round | 13.5M |
6/2018 | ENYO Pharma | Series B | 46.8M |
8/2011 | Vessix Vascular | Series B | 0 |
4/2015 | ACE Group | Venture Round | - |
8/2020 | T-knife | Series A | 78.4M |
9/2015 | ReViral | Series A | 21M |
11/2012 | Endosense | Series C | 40.3M |
7/2016 | Mondial Pet Distribution | Venture Round | 16.6M |
7/2012 | Medcdtll | Venture Round | - |
9/2004 | Santen Pharmaceutical | Post-IPO Equity | 11.2M |
5/2010 | Noxxon Pharma | Series D | 40.7M |
6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
4/2019 | HR Path | Private Equity Round | 112.4M |
2/2005 | MeeVee | Series A | 7M |
11/2021 | ImmoCity | Venture Round | - |
11/2017 | erytech | Post-IPO Equity | - |
7/2016 | Atland | Venture Round | 3.3M |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
11/2014 | Finsecur | Venture Round | 31.2M |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
5/2007 | Implanet | Series A | 17.7M |
12/2019 | Mastergrid | Private Equity Round | - |
1/2011 | Novamex SA | Private Equity Round | - |
10/2014 | Maesa Group | Venture Round | - |
12/2018 | The Bioclinic Group | Private Equity Round | - |
6/2013 | MCI Group Holding | Private Equity Round | - |
6/2013 | Complix | Series B | 15.6M |
3/2015 | Ace Credit | Private Equity Round | - |
12/2018 | Solware Group | Private Equity Round | - |
4/2017 | Bacacier group | Private Equity Round | - |
2/2018 | Biogroup-LCD | Debt Financing | - |
11/2016 | NetCo | Venture Round | - |
5/2004 | Domain Therapeutics | Series B | 19.1M |
6/2015 | Rougnon | Private Equity Round | - |
5/2019 | SPHEREA | Venture Round | - |
5/2007 | Noxxon Pharma | Series C | 50.2M |
9/2017 | Loyalty Company | Venture Round | - |
11/2007 | EOS Imaging | Venture Round | 18M |
3/2014 | Inotrem | Series A | 25.1M |
9/2014 | Poxel | Series B | 13.5M |
6/2017 | LogicBio Therapeutics | Series B | 45M |
10/2007 | Fastbooking | Venture Round | 50.4M |
10/2016 | The Reefer Group | Private Equity Round | - |
7/2010 | Implanet | Series D | 10.1M |
1/2013 | ITESA | Private Equity Round | - |
2/2020 | JenaValve Technology | Venture Round | 50M |
3/2014 | Axonics Modulation Technologies | Series A | 32.6M |
4/2014 | Passman | Private Equity Round | - |
1/2020 | Grey Wolf Therapeutics | Series A | 3.3M |
7/2022 | Resonance Imaging Group | Venture Round | - |
2/2011 | CellNovo | Series B | 48.3M |
8/2018 | ReViral | Series B | 0 |
7/2017 | Complexa | Series C | 62M |
3/2023 | FIRE1 | Venture Round | 0 |
6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
2/2019 | Grey Wolf Therapeutics | Series A | 12.9M |
6/2022 | Mineralys Therapeutics | Series B | 0 |
5/2022 | HR Path | Private Equity Round | 0 |
2/2019 | Arvelle Therapeutics | Series A | 0 |
9/2022 | Tricares | Series C | 0 |
9/2007 | MeeVee | Series D | 3.5M |
4/2018 | MMI | Series A | 24.8M |
7/2022 | MMI | Series B | 0 |
1/2015 | Genkyotex | Post-IPO Equity | 0 |
1/2016 | Sfam | Private Equity Round | - |
12/2015 | GamaMabs Pharma | Series B | 16.4M |
12/2012 | Regado Biosciences | Series E | 0 |
5/2011 | Genkyotex | Series C | 20.4M |
11/2010 | Covagen | Series A | 6.3M |
7/2012 | Genkyotex | Series C | 25.6M |
12/2013 | Covagen | Series B | 0 |
8/2021 | T-knife | Series B | 110M |
8/2022 | JenaValve Technology | Series C | 0 |
5/2022 | Tubulis | Series B | 0 |
4/2010 | Implanet | Series C | 10.8M |
8/2013 | OncoEthix | Series B | 0 |
1/2017 | Avalyn Pharma | Series A | 0 |
5/2017 | Genoa Pharmaceuticals | Series A | 62M |
5/2023 | Dualyx | Series A | 0 |
3/2020 | AM Pharma | Venture Round | 25.4M |
10/2009 | Endosense | Series B | 0 |
5/2015 | Realeve | Series D | 38M |
4/2018 | Corvidia | Series B | 60M |
12/2015 | Axonics Modulation Technologies | Series B | 0 |
3/2021 | AgomAb Therapeutics | Series B | 0 |
9/2021 | Evommune | Series A | 83M |
4/2023 | Evommune | Series B | 50M |
7/2011 | Sun City Group, Inc. | Venture Round | - |
4/2013 | Genticel | Series D | 23.7M |
7/2019 | Travelsoft | Private Equity Round | - |
11/2017 | walor | Private Equity Round | - |
7/2017 | Groupe 3S | Private Equity Round | - |
9/2012 | Alouette | Private Equity Round | - |
10/2018 | Groupe JORYF | Private Equity Round | - |
1/2010 | Smile | Venture Round | 3.6M |
1/2019 | Exciva | Seed Round | - |
7/2017 | Studia group | Private Equity Round | - |
5/2015 | Altavia | Venture Round | - |
12/2018 | T-knife | Seed Round | 9.1M |
4/2008 | AJ Tech | Series A | 1.3M |
9/2017 | Intech | Private Equity Round | - |
8/2020 | ReViral | Series C | 0 |
9/2012 | DEFI Group | Private Equity Round | - |
7/2018 | orbility | Private Equity Round | - |
9/2015 | Pennel &a; Flipo | Private Equity Round | - |
12/2019 | Opportunity | Private Equity Round | - |
11/2014 | A2IA | Private Equity Round | - |
3/2016 | La Toulousaine | Private Equity Round | - |
7/2016 | Ipside | Venture Round | 3.3M |
5/2020 | Arvelle Therapeutics | Series A | 0 |
7/2010 | Poxel | Series A | 21M |
6/2018 | Tricares | Series B | 25.7M |
2/2010 | PDC Biotech | Series A | 5.5M |
4/2019 | Tournus Equipement | Private Equity Round | - |
4/2023 | Ariceum Therapeutics | Series A | 0 |
4/2023 | BioVentrix | Series A | 0 |
3/2023 | FIRE1 | Venture Round | 0 |
1/2023 | Grey Wolf Therapeutics | Series B | 0 |
1/2023 | SoniVie | Series C | 0 |
1/2023 | Amolyt Pharma | Series C | 0 |
10/2022 | Senstronic | Venture Round | - |
9/2022 | Tricares | Series C | 0 |
8/2022 | JenaValve Technology | Series C | 0 |
7/2022 | MMI | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|